Laboratory Products 71 Report on Nanoparticle Tracking Analysis use in the Brno Veterinary Research Institute
The central theme of Dr Jaroslav Turanek’s research group (Department of Pharmacology and Immunotherapy), at the Veterinary Research Institute in Brno, Czech Republic, is to apply synthetic and bioorganic chemistry. This work is performed in collaboration with King’s College London and the Institute of Organic Chemistry and Biochemistry, Prague, for the design and construction of therapeutic nanoparticles to develop drug delivery systems and nanocarriers for construction of recombinant vaccines.
In parallel, the research group of Dr Miroslav Machala (Department of Chemistry and Toxicology) at Veterinary Research Institute focuses upon environmental nanoparticulate pollutants. Characterisation of airborne particles is conducted using electron microscopy, but in vitro tests on cell culture require knowledge of the real structure of nanoparticles in the tissue culture medium.
Detailed particle distribution and kinetics of aggregation in this heterogeneous system is impossible to obtain using electron microscopy and hence Nanoparticle Tracking Analysis, NTA, is the method of choice. It is noted that some metastable aggregates can disaggregate due to high dilution of the sample required for NTA analysis. For this reason, Dynamic Light Scattering, DLS, and NTA are used as suitable complementary methods in the laboratory.
The Malvern NanoSight NS500 system is used in the VRI laboratories as alongside other techniques including DLS (Zetasizer Nano ZS), static light scattering, Gel Permeation Chromatography, electron microscopy and Field Flow Fractionation.
Explaining their choice of NanoSight, Dr Turanek said: “We chose NTA as a convenient and rapid method for characterisation of nanoparticles in heterogeneous preparations like liposomes and their complexes with proteins, DNA and polysaccharides. A set of these techniques is used for the complex characterisation of the structure of the nanoparticles, the kinetics of their preparation, the dynamics of morphological transformation and, fi nally, their stability. NTA perfectly fi ts our needs and has become a standard method in our methodological portfolio. The most advantageous feature of NTA is that it makes it possible to visualise each nanoparticle and then to obtain more detailed size distributions based on individual particle measurements. DLS is used as precise complementary method for the characterisation of nanoparticles below 20 nm for proteins and other biopolymers. Combination of these two methods, NTA and DLS, with separation methods (GPC, FFF) and electron microscopy is preferred to get the full insight to structure and dynamics of nanoparticles in our sample systems.”
28038pr@reply-direct.com
High Containment Barrier Systems Designed for API’s Manufacturing and Research of new Products Developed
Telstar has successfully developed two high containment barrier systems for the Korean Komipharm Pharmaceuticals Co Ltd, one of the largest producers of products from anti-cancer drugs in human oral dosage form to veterinary medicines in Asia. The systems, one for API Sampling and the other for QC Sample Handling will be used in Komipharm’s new facility, built in the South Korean city of Cheongwon, Chungcheongbuk-do. The purpose of the systems is to provide a high level of containment to protect operators during the manufacturing process using API’s (Active Pharmaceutical Ingredients). Additionally, the systems will be utilised in research in the biotechnology fi eld aimed to develop vaccines by genetic technology.
Specifi cally designed for handling hazardous products, these containment systems run at negative pressure to the surrounding room providing operator protection during the manual product handling process and environmental protection for the product by virtue of the standard ISO 7 classifi cation inside the Isolator.
This project has been carried out by the Technology Centre for Barrier Isolation Systems of Telstar, located in Dewsbury (UK).
The two containment barrier systems developed by Telstar have been specially designed to handle API’s during pharmaceutical manufacturing and analytical testing of product containing raw arsenic. One of the Isolator systems is for API Sampling and the other for QC Sample Handling. Both systems are based around the Telstar standard containment range to optimise cost effi ciency, thus minimising design and assembly hours. Because of the standard design, the routine maintenance and every day running procedures are simplifi ed and more cost effi cient. Additionally, many of the featured parts are common, versatile and inter-changeable, which enables the client to avoid the over stocking of spares.
The ergonomically trialled barrier containment system supplied to Komipharm stands out by its simplicity regarding the base design and control system, coupled with optional accessory enhancement to offer fl exibility and adaptation if required in the future.
27678pr@reply-direct.com
For a better way to get your message across...
The A-Z of reusable plastic labware
For more than half a century the Azlon name has been synonymous with high quality affordable plastic laboratory ware. Azlon offers more than 700 plastic laboratory products including bottles, wash bottles, measuring cylinders, jugs and beakers.
For more information about our products please visit our website
www.scilabware.com
SciLabware Ltd., Unit 4, Riverside 2, Campbell Road, Stoke on Trent, ST4 4RJ, UK Tel: +44 (0)1782 444406 Fax: +44 (0)1782 940436
www.scilabware.com
Contact:
sales@intlabmate.com
1283ad@reply-direct.com
WWW.LABMATE-ONLINE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96
